These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23803980)

  • 1. Case report series of left atrial thrombus formation in patients on dabigatran therapy.
    Sharma S; Singh S; Sandhu R; Monterroso M; Bhambi N; Sharma R
    Am J Ther; 2014; 21(3):e71-4. PubMed ID: 23803980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
    Bovio JA; Smith SM; Gums JG
    Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rash associated with dabigatran etexilate.
    To K; Reynolds C; Spinler SA
    Pharmacotherapy; 2013 Mar; 33(3):e23-7. PubMed ID: 23400964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemopericardium in a patient treated with dabigatran etexilate.
    Barton CA; McMillian WD; Raza SS; Keller RE
    Pharmacotherapy; 2012 May; 32(5):e103-7. PubMed ID: 22488474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
    Baruch L; Sherman O
    Ann Pharmacother; 2011 Jul; 45(7-8):e40. PubMed ID: 21712509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran etexilate for venous thromboembolism: a safety evaluation.
    Brown R; Lip GY; Gallego P
    Expert Opin Drug Saf; 2014 May; 13(5):639-47. PubMed ID: 24598005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
    Galanis T; Merli GJ
    Hosp Pract (1995); 2013 Feb; 41(1):26-36. PubMed ID: 23466965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM; Qureshi AI
    Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.
    Kuwauchi S; Watanabe S; Abe K; Yamasaki M; Ito J; Kawazoe K
    Ann Thorac Surg; 2013 Nov; 96(5):1863-4. PubMed ID: 24182477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran in clinical practice.
    Nagarakanti R; Ellis CR
    Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dabigatran as an alternative to warfarin for the prevention of thromboembolism in atrial fibrillation].
    De Caterina R; Renda G
    G Ital Cardiol (Rome); 2012 Nov; 13(11 Suppl 1):19S-27S. PubMed ID: 23160016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.
    Chin PK; Wright DF; Patterson DM; Doogue MP; Begg EJ
    Br J Clin Pharmacol; 2014 Sep; 78(3):599-609. PubMed ID: 24592851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
    Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
    Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
    Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
    Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature.
    Hohnloser SH; Camm AJ
    Europace; 2013 Oct; 15(10):1407-11. PubMed ID: 23954917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
    Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
    Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.